Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

Home
/
insight
/
details

MSI: A Catalyst for Personalized Cancer Care and Therapeutic Innovation

NextEdge Admin

05 May 2024

3 min 7 sec

Microsatellite instability (MSI) is a phenomenon crucial in understanding certain aspects of cancer biology and treatment. At its core, MSI reflects a malfunction in the cell’s ability to repair errors that occur during DNA replication, particularly in short repeating sequences called microsatellites. These sequences, akin to genetic fingerprints, are normally stable due to the cell’s meticulous error-correction mechanisms. However, when these mechanisms falter, as in cases of mismatch repair deficiency, microsatellites become unstable.

In cancer, MSI holds significant implications. While once considered a harbinger of poor prognosis in advanced cancers, recent advancements in immunotherapy have reshaped this narrative. MSI-high cancers, characterized by rampant mutations and protein alterations, become more visible to the immune system. This heightened immunogenicity renders them susceptible to immunotherapeutic interventions, offering new hope for patients previously facing limited treatment options.

Clinically, identifying MSI has become increasingly important, particularly in colorectal cancer where universal testing is now standard practice. Though MSI remains relatively rare across cancer types, its impact on treatment outcomes underscores the necessity for broader screening efforts. As our understanding of MSI continues to evolve, so does its role in shaping personalized cancer care.

Selecting the best method for testing microsatellite instability (MSI) hinges on factors like sensitivity, specificity, and resource accessibility. PCR-based assays offer cost-effective, high sensitivity, but require specialized equipment. Immunohistochemistry (IHC) provides direct MMR protein expression evidence and is widely available. Next-generation sequencing (NGS) offers comprehensive genomic analysis but demands specialized expertise and equipment. Combining methods, such as PCR and IHC, can bolster MSI detection accuracy and clinical decision-making, facilitating a tailored approach based on the unique needs of each clinical scenario.

MSI exemplifies the intricate interplay between genetics, tumor biology, and therapeutic innovation. Its recognition not only illuminates the underlying mechanisms driving cancer progression but also heralds a promising era in precision oncology, where tailored treatments capitalize on the vulnerabilities inherent in tumor biology.